Phase III
The U.S. Food and Drug Administration is set to rule on Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor, for adult patients with chronic or persistent immune thrombocytopenia (ITP) on April 17.
During the J.P. Morgan Healthcare Conference, Sage provided an update on its long-term strategy to drive growth at the company.
Shares of Diffusion Pharma shot up more than 40 percent Tuesday after the company provided an overview of the company and its Phase III candidate.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
Kala Pharma released mostly positive topline results from two Phase III clinical trials for KPI-121 in patients with dry eye disease.
The decision was largely expected given the time of the year and the fact the trial hasn’t yet been initiated.
Zhejiang Medicine has terminated its Phase III oncology trial for oral forms of prochloridine mesylate to treat AML due to a lack of efficacy.
Shares of Agile plunged more than 62 percent in early trading after the company announced this morning the FDA rejected its low-dose hormonal contraceptive patch called Twirla.
Celgene announced the Phase III results late Thursday and share prices dropped about 4 percent to $102.69 as of 9:30 this morning.
Italfarmaco has its eyes set on bringing a new treatment that targets the underlying mechanism of the blood disorder Polycythemia Vera.
PRESS RELEASES